Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Prognostic Impact of Smoking on Bevacizumab Combination Chemotherapy for Advanced Breast Cancer

KOJI TAKADA, SHINICHIRO KASHIWAGI, NOZOMI IIMORI, RIKA KOUHASHI, AKIMICHI YABUMOTO, WATARU GOTO, YUKA ASANO, YUKIE TAUCHI, KANA OGISAWA, TAMAMI MORISAKI, MASATSUNE SHIBUTANI, HIROAKI TANAKA and KIYOSHI MAEDA
Anticancer Research February 2023, 43 (2) 849-856; DOI: https://doi.org/10.21873/anticanres.16227
KOJI TAKADA
1Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINICHIRO KASHIWAGI
1Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: spqv9ke9@view.con.ne.jp
NOZOMI IIMORI
1Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RIKA KOUHASHI
1Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKIMICHI YABUMOTO
1Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WATARU GOTO
1Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKA ASANO
1Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKIE TAUCHI
1Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KANA OGISAWA
1Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAMAMI MORISAKI
1Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASATSUNE SHIBUTANI
2Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROAKI TANAKA
2Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KIYOSHI MAEDA
2Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Smoking has been a proven carcinogenic risk factor for various cancers, including breast cancer. Furthermore, smoking has been recognized as a prognostic factor of breast cancer. Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) used in combination with chemotherapy to treat breast cancer. We, herein, investigated the effect of smoking on the prognosis of unresectable breast cancer patients who received bevacizumab plus weekly paclitaxel. Patients and Methods: From April 2011 to June 2022, 131 patients received bevacizumab plus weekly paclitaxel for unresectable breast cancer. At their first visit to our hospital, smoking status (i.e., period of smoking and amount of smoking per day) was evaluated by interview, and packs-years were calculated. Results: Time to treatment failure (TTF) was significantly longer in the high packs-years group than the low packs-years group (p=0.010, log-rank). The log-rank test showed that the high packs-years group had a significantly longer overall survival than the low packs-years group (p=0.049, log-rank). Multivariate analysis of TTF revealed that progesterone receptor (p=0.005, HR=0.408) and packs-years (p=0.007, HR=0.391) were independent factors. Conclusion: A history of smoking may impact prognosis of combination chemotherapy with bevacizumab for advanced breast cancer treatment.

Key Words:
  • Breast cancer
  • smoking
  • bevacizumab
  • chemotherapy
  • prognosis
  • Received November 18, 2022.
  • Revision received December 3, 2022.
  • Accepted January 3, 2023.
  • Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 43 (2)
Anticancer Research
Vol. 43, Issue 2
February 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prognostic Impact of Smoking on Bevacizumab Combination Chemotherapy for Advanced Breast Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Prognostic Impact of Smoking on Bevacizumab Combination Chemotherapy for Advanced Breast Cancer
KOJI TAKADA, SHINICHIRO KASHIWAGI, NOZOMI IIMORI, RIKA KOUHASHI, AKIMICHI YABUMOTO, WATARU GOTO, YUKA ASANO, YUKIE TAUCHI, KANA OGISAWA, TAMAMI MORISAKI, MASATSUNE SHIBUTANI, HIROAKI TANAKA, KIYOSHI MAEDA
Anticancer Research Feb 2023, 43 (2) 849-856; DOI: 10.21873/anticanres.16227

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Prognostic Impact of Smoking on Bevacizumab Combination Chemotherapy for Advanced Breast Cancer
KOJI TAKADA, SHINICHIRO KASHIWAGI, NOZOMI IIMORI, RIKA KOUHASHI, AKIMICHI YABUMOTO, WATARU GOTO, YUKA ASANO, YUKIE TAUCHI, KANA OGISAWA, TAMAMI MORISAKI, MASATSUNE SHIBUTANI, HIROAKI TANAKA, KIYOSHI MAEDA
Anticancer Research Feb 2023, 43 (2) 849-856; DOI: 10.21873/anticanres.16227
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study
  • Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series
  • Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
Show more Clinical Studies

Similar Articles

Keywords

  • breast cancer
  • smoking
  • bevacizumab
  • chemotherapy
  • prognosis
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire